Farallon Capital Management’s Beam Therapeutics BEAM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $170M | Buy |
10,013,111
+85,000
| +0.9% | +$1.45M | 0.73% | 37 |
|
|
2025
Q1 | $194M | Buy |
9,928,111
+1,688,988
| +20% | +$33M | 0.96% | 34 |
|
|
2024
Q4 | $204M | Buy |
8,239,123
+31,000
| +0.4% | +$769K | 0.91% | 35 |
|
|
2024
Q3 | $201M | Buy |
8,208,123
+295,000
| +4% | +$7.23M | 0.89% | 34 |
|
|
2024
Q2 | $185M | Buy |
7,913,123
+3,401,370
| +75% | +$79.7M | 0.8% | 36 |
|
|
2024
Q1 | $149M | Buy |
4,511,753
+406,000
| +10% | +$13.4M | 0.63% | 37 |
|
|
2023
Q4 | $112M | Sell |
4,105,753
-376,086
| -8% | -$10.2M | 0.51% | 43 |
|
|
2023
Q3 | $108M | Buy |
4,481,839
+1,040,317
| +30% | +$25M | 0.5% | 38 |
|
|
2023
Q2 | $110M | Buy |
3,441,522
+9,601
| +0.3% | +$307K | 0.55% | 46 |
|
|
2023
Q1 | $105M | Buy |
3,431,921
+32,000
| +0.9% | +$980K | 0.57% | 47 |
|
|
2022
Q4 | $133M | Sell |
3,399,921
-231,350
| -6% | -$9.05M | 0.79% | 40 |
|
|
2022
Q3 | $173M | Buy |
3,631,271
+159,000
| +5% | +$7.57M | 0.95% | 37 |
|
|
2022
Q2 | $134M | Buy |
3,472,271
+877,884
| +34% | +$34M | 0.73% | 43 |
|
|
2022
Q1 | $149M | Buy |
2,594,387
+329,342
| +15% | +$18.9M | 0.72% | 37 |
|
|
2021
Q4 | $181M | Buy |
2,265,045
+547,455
| +32% | +$43.6M | 0.9% | 32 |
|
|
2021
Q3 | $149M | Buy |
1,717,590
+217,590
| +15% | +$18.9M | 0.7% | 40 |
|
|
2021
Q2 | $193M | Buy |
1,500,000
+907,519
| +153% | +$117M | 0.79% | 36 |
|
|
2021
Q1 | $47.4M | Buy |
+592,481
| New | +$47.4M | 0.24% | 73 |
|
|
2020
Q2 | – | Sell |
-170,164
| Closed | -$3.06M | – | 119 |
|
|
2020
Q1 | $3.06M | Buy |
+170,164
| New | +$3.06M | 0.03% | 89 |
|